Welcome to our dedicated page for NOVANTA SEC filings (Ticker: NOVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novanta Inc. filings document the company's operating results, governance matters and capital structure as an operating technology supplier to medical and advanced technology equipment manufacturers. Form 8-K reports furnish earnings releases and financial guidance updates, report board and committee changes, and disclose authorizations for common-share repurchases.
The company's filings also include capital-markets disclosures for Novanta's 6.50% tangible equity units, including underwriting arrangements, unit issuance and related registration-statement references. The definitive proxy statement covers shareholder voting matters, board governance, executive compensation, equity awards and pay-versus-performance information for the company's annual meeting process.
Novanta Inc. completed the acquisition of Riverpoint Medical by purchasing all equity of Runway Buyer on July 23, 2026. Buyer parties paid approximately $1.2 billion in cash at closing, plus a potential $250.0 million milestone payment due on or before January 8, 2027.
To fund the deal, an indirect subsidiary borrowed $616.0 million under its revolving and delayed draw term loan facilities, with the remainder from cash on hand, bringing consolidated debt to $854.7 million. The credit facilities mature in June 2030 and may be repaid early without penalty. Novanta states the acquisition is expected to roughly double recurring medical consumables revenue to $300 million, increase medical end-market exposure to 60% of total revenue, be immediately accretive to organic growth, margins, adjusted EBITDA and cash flows, and add $0.18–$0.25 of adjusted EPS in 2027.
Novanta Inc. Chief Executive Officer Matthijs Glastra reported open-market sales of 6,500 shares of Novanta common stock. The transactions occurred on July 2, 2026 across five trades at reported prices between $160.13 and $164.20 per share, classified as open-market sales.
The filing states these sales were effected under a pre-established Rule 10b5-1 trading plan adopted on September 11, 2025 through a trust for which his spouse is a trustee. Following the transactions, Glastra holds 29,761 shares directly and 54,382 shares indirectly through the Matthijs Glastra 2021 Irrevocable Trust.
Novanta, Inc. notice of proposed sales of Common Stock by affiliates under Form 144. The excerpt lists recent restricted stock unit grants and multiple reported sales by Matthijs Glastra in the past three months, including 7,500 shares on 05/12/2026.
Novanta Inc. is registering the resale of 2,142,857 common shares sold in a June 2026 private placement; the company will not receive proceeds from these resales.
The shares were issued at $140.00 per share in the private placement for an aggregate purchase price of approximately $300.0 million. The prospectus states the selling shareholders may sell the shares from time to time in one or more offerings and that supplements will disclose specific offering terms. Shares outstanding were 37,756,160 as of June 15, 2026, and the prospectus cites a last reported Nasdaq sale price of $157.55 on June 26, 2026.
Novanta Inc. entered into a Securities Purchase Agreement for a private placement of common shares expected to raise gross proceeds of approximately $300 million. Institutional and other accredited investors agreed to buy 2,142,857 common shares at $140.00 per share, with closing targeted for June 11, 2026, subject to customary conditions.
The shares are being sold in an unregistered transaction under Section 4(a)(2) of the Securities Act, and Novanta agreed in a Registration Rights Agreement to register their resale after closing. As of June 8, 2026, Novanta had 35,613,303 common shares outstanding; including a minimum 4,717,185 shares issuable under Tangible Equity Units, there would be 42,473,345 common shares outstanding or issuable following the closing.
Novanta Inc. is making a major move into minimally invasive surgical consumables by agreeing to acquire Riverpoint Medical for an upfront cash payment of $1.2 billion, plus a $250 million milestone payment expected in early 2027.
Riverpoint generates about $150 million in revenue with >50% adjusted gross margins, ~40% adjusted EBITDA margins and a 12%–15% organic growth outlook, roughly twice Novanta’s current growth rate. Novanta expects the deal to double recurring medical consumables revenue to roughly $300 million and increase medical end-market exposure to about 60% of total sales.
The transaction is expected to be immediately accretive to Novanta’s Adjusted Diluted EPS in 2026, and in 2027 accretive to revenue growth, adjusted margins, earnings and operating cash flow. It will be funded with cash on hand, existing credit facilities and a completed $300 million equity raise, with a targeted net leverage ratio of about 2.7x at closing and below 2.3x by year-end 2027.
Novanta Inc. director and CEO Matthijs Glastra reported open-market sales of 6,500 shares of common stock on June 2, 2026. The shares were sold in multiple transactions at prices ranging from $164.61 to $171.28, according to the Form 4 data.
The filing shows Glastra now directly owns 36,261 Novanta shares and indirectly holds 54,382 shares through the Matthijs Glastra 2021 Irrevocable Trust. The sales were executed under a pre-established Rule 10b5-1 trading plan adopted on September 11, 2025, indicating they were pre-arranged rather than discretionary trades.
Novanta, Inc. submitted an amendment to a Form 144 that lists notices of proposed sales of Common stock. The filing names Merrill Private Wealth Management as an intermediary and records multiple sale entries of 6,500 shares and one entry of 7,500 shares on specific dates in 2026.
Novanta, Inc. (NOVT) submitted a Form 144 notice showing holder/sponsor activity for Common Stock. The filing lists 7,500 shares associated with Merrill Private Wealth Management and multiple restricted stock unit lots (3,618; 1,744; 1,870; 268) with grant dates between 02/26/2017 and 02/25/2020. The excerpt also lists recent reported sales by Matthijs Glastra: 7,500 shares on 02/10/2026, 6,500 shares on 03/02/2026, 6,500 shares on 04/17/2026, and 6,500 shares on 05/05/2026.
Novanta Inc. reported the results of its 2026 annual meeting of shareholders. A total of 33,371,777 common shares were represented, equal to 93.71% of outstanding shares as of April 14, 2026. All nine director nominees received strong majority support and were elected for terms ending at the 2027 annual meeting.
Shareholders also approved, on an advisory basis, the Company’s executive compensation and ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm through the next annual meeting.